Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications
/in Acute Leukemia, International PublicationsThe efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience
/in Acute Leukemia, Dendritic Cells, International PublicationsPotential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia
/in Acute Leukemia, International PublicationsEfficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy
/in Acute Leukemia, International PublicationsQuantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia
/in Acute Leukemia, International PublicationsLarge-scale generation of autologous dendritic cells for immunotherapy in patients with acute myeloid leukemia
/in Acute Leukemia, International PublicationsDendritic cell vaccines for leukemia patients
/in Acute Leukemia, Chronic Leukemia, International PublicationsDendritic cell-based immunotherapy in acute and chronic myeloid leukaemia
/in Acute Leukemia, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer